Christoph Boss

This inventor holds 59 USPTO granted patents and 15 published patent applications, plus 14 CIPO patents and 42 EPO patents, primarily in Orexin Receptor Antagonists (CPC class C07D). Top assignees: Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd. Active years: 2003-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christoph Boss. Retrieved from https://idiyas.com/inventor/christoph-boss

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 59 (Patent Applications = 15)

% Patents Active = 42.4

CIPO Patents = 14 (Patent Applications = 12)

EPO Patents = 42 (Patent Applications = 44)

Average Co-Inventor Count = 5.6

ph-index = 10

Forward Citations = 272(Granted Patents)

Forward Citations (Not Self Cited) = 158(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

43 out of 217

Actelion Pharmaceuticals Ltd

patents

16 out of 81

Idorsia Pharmaceuticals Ltd

patents

Years Active: 2003-2023

Loading Chart...

Areas of Expertise:

Orexin Receptor Antagonists

PGE2 Receptor Modulators

NADPH Oxidase Inhibitors

Benzimidazole-Proline Derivatives

Azaindole Acetic Acid Derivatives

Proline Sulfonamide Derivatives

Phenyl Derivatives

Pyrimidine Derivatives

Crystalline Forms

Acrylamide Derivatives

Thiazolidine Derivatives

Heterocyclyl Derivatives

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11839613 - Pyrimidine derivatives as PGE2 receptor modulators (2023-12-12),

2. 11712438 - Phenyl derivatives as PGE2 receptor modulators (2023-08-01),

3. 11446298 - Pyrimidine derivatives (2022-09-20),

4. 11325899 - Benzofurane and benzothiophene derivatives as PGE2 receptor modulators (2022-05-10),

5. 11267824 - Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase (2022-03-08),

6. 11136317 - NADPH oxidase 4 inhibitors (2021-10-05),

7. 11040966 - Benzimidazole-proline derivatives (2021-06-22),

8. 10584118 - NADPH oxidase 4 inhibitors (2020-03-10),

9. 10351560 - Crystalline forms (2019-07-16),

10. 10329287 - Benzimidazole-proline derivatives (2019-06-25),

11. 10301309 - Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators (2019-05-28),

12. 10023560 - Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist (2018-07-17),

13. 9914721 - Use of benzimidazole-proline derivatives (2018-03-13),

14. 9914720 - Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists (2018-03-13),

15. 9879006 - [object Object] (2018-01-30),

Title: The Innovative Journey of Christoph Boss

Introduction:

Christoph Boss, a visionary inventor hailing from Allschwil, Switzerland, has made significant contributions to the world of technology and innovation.

Latest Patents:

Christoph Boss holds several patents in the field of biotechnology, with his most recent inventions focusing on advanced drug delivery systems and personalized medicine.

Career Highlights:

With a background in bioengineering, Christoph Boss has dedicated his career to developing cutting-edge solutions for healthcare challenges. His work has been instrumental in revolutionizing the way medications are administered and personalized for patients.

Collaborations:

Throughout his career, Christoph Boss has collaborated with leading pharmaceutical companies, research institutions, and universities to bring his inventions to life. His collaborative spirit has led to groundbreaking advancements in the field of biotechnology.

Conclusion:

In conclusion, Christoph Boss stands as a beacon of innovation in the field of biotechnology, with a passion for improving healthcare outcomes through his groundbreaking inventions. His dedication to pushing the boundaries of what is possible continues to inspire the next generation of inventors and researchers.

Profile summary based on public USPTO records.